Ischemix was granted US 7,928,067 B2 patent entitled "Compositions and Methods for Treating Ischemia and Ischemia-reperfusion Injury" with a priority date of May 2009. Claims include composition of matter for CMX-2043 drug substance, drug product and pro-drugs. CMX-2043 was used in a Phase 2a clinical trial for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures.
